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Assessing the potential economic benefits to farmers from various GM crops becoming 1 
available in the European Union by 2025: results from an expert survey 2 
1. Introduction 3 
Evidence is being presented in many quarters that genetically modified (GM) crops have 4 
delivered net benefits for farmers, both small and large scale, and consumers, in the countries 5 
where cultivation has been permitted (e.g. Brookes & Barfoot, 2016 and James, 2014). 6 
Depending on the crop and trait, these benefits might be agronomic, economic and/or 7 
environmental in nature, resulting from yield improvements, better management of pests and 8 
diseases, reduced input use and nutritional improvements.  While there are a growing number 9 
of commercially-grown GM crops in the world, only one GM crop is currently permitted for 10 
cultivation in the European Union (EU) i.e. Bt maize. While Bt maize cultivation occurred in 11 
five EU countries in 2014, the areas cultivated were very small, with only Spain and Portugal 12 
producing more than a few thousand hectares i.e. 131,537 ha (MAGRAMA, 2014) and 8,542 13 
ha (Ministry of Agriculture and Sea of Portugal, 2014) respectively. As the House of 14 
Commons (2015) points out, the fact that there is only one GM crop approved for cultivation 15 
is largely due to the extremely slow and cumbersome EU GM approvals process, which 16 
requires majority member state approval in the European Council, resulting in an effective 17 
moratorium on further authorisations in the EU.  As a consequence of this extremely arid 18 
policy environment, private sector investment in GM technology has moved out of the EU 19 
and consequently there is very little research being undertaken specifically focused on the 20 
needs of EU agriculture or consumers.  It is, therefore, unsurprising to note that some 21 
commercial biotech companies have started to withdraw pending applications for EU 22 
authorisations for GM technologies that they have developed (EC, 2016a).  23 
 24 
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However, this ‘informal’ moratorium on GM authorisations within the EU might soon 25 
be lifted, as a consequence of recent changes to legislation. Directive (EU) 2015/412 26 
of the European Parliament and of the Council of 11 March 2015, amending Directive 27 
2001/18/EC, provides the means for the Member States to restrict or prohibit, on 28 
certain grounds, the cultivation of genetically modified organisms (GMOs) in their 29 
territory, even when these have been judged by the EU’s regulators to pose no risk to 30 
human health or the environment (European Parliament and Council, 2015). Allowing 31 
Member States to unilaterally ban GM cultivation may not sound like much of a 32 
breakthrough for GM authorizations, but the rationale for allowing Member States to 33 
‘opt out’ of GM cultivation in this way, is that they will not need to block agreement 34 
on GM authorisations within the European Council to maintain their own GM-free 35 
status, thereby making EU-level authorisations easier to obtain. 36 
 37 
Outside of the EU, the development pipeline continues to produce new 38 
commercialized GM crops. The USDA Animal and Plant Health Inspection Service 39 
(APHIS), which regularly publishes lists of successful petitions for unregulated release 40 
of GM events into the environment in the USA, announced in September 2015 that the 41 
117th such petition, for a potato with blight-resistance (Pathogen Tolerant - PT) and 42 
other properties, was approved for trials (APHIS, 2015).  While there has been no 43 
incentive for commercial biotech companies to develop crop-trait combinations 44 
targeted at agronomic conditions prevailing in Europe, Stein and Rodriguez-Cerezo 45 
(2009) have noted that some GM crops already commercialized outside the EU, or 46 
within the development pipeline, are both agronomically suitable and may offer 47 
potential benefits for farmers or consumers in the EU. With a potential unblocking of 48 
the EU GM crop authorisation process now a distinct possibility, leading to some 49 
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countries in the EU (such as an independent post-Brexit UK) considering adoption of 50 
GM crops, it is timely to review the GM crop-trait combinations that were currently, 51 
or soon to be available, to identify their suitability for cultivation in the EU and 52 
examine the nature of the benefits that they might offer to either farmers and/or 53 
consumers.  54 
 55 
Almost all past evaluations of the benefits offered by potential uptake of GM technologies in 56 
the EU have focussed on the farm-scale economic benefits offered by the most common GM 57 
crops (soybean, maize, cotton and canola) and traits (herbicide tolerance [HT] and insect 58 
resistance [IR] (Kathage et al., 2016).  This concentration on crop-trait combinations already 59 
commercialised (see, for example, Demont and Tollens, 2004; Demont et al., 2007; Brookes, 60 
2007; Demont et al., 2008; Dillen et al., 2009; Carpenter, 2010) has occurred for the practical 61 
reason that these cases provide some data on the benefits obtained from adoption available 62 
from non-EU settings, or at least from field-scale trials.  As Kathage et al. (2016) pointed out, 63 
the availability of data remains the primary constraint to evaluation of the impacts of GM 64 
crops in the EU setting.  An exception to this trend is Flannery et al. (2004) who included 65 
some ‘hypothetical’ crop-trait combinations in a benefits evaluation for Ireland.  For the 66 
study detailed here, it was concluded that because the policy and regulatory changes required 67 
to ‘open up’ EU member states to GM crop production was likely to take a number of years, 68 
the scope of this analysis could not be confined to GM technologies already commercialised, 69 
but must also have to take into account crop-trait combinations still in development, that are 70 
likely to be available in the near future, say by 2025.      71 
The novel approach taken in the evaluation presented here i.e. extending the scope of the 72 
analysis to include GM crops not yet commercialised, presented an obvious methodological 73 
problem: that of obtaining data on the likely benefits from uptake of crops where no 74 
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observational data were available.  Past approaches to estimate likely benefits from GM crops 75 
grown in the EU have involved extensive surveys of non-EU production thus providing data 76 
for transfer into the EU context.  When such approaches were not possible i.e. where only 77 
limited data were available, modelling exercises have been undertaken (see, for example, 78 
Demont and Tollens, 2004), sometimes involving statistical approaches, such as stochastic 79 
simulation techniques to overcome concerns about the accuracy or representativeness of the 80 
data.  However, for most crops considered here, because they are yet to be commercialised, 81 
no data are available at all.  To overcome this problem, we adopted the only remaining 82 
approach that could supply credible benefits data – stakeholder consultation, where a panel of 83 
experts in GM technologies provided estimates of likely future benefits of GM adoption.  84 
This approach was also applied to crop-trait combinations that are commercialised outside of 85 
the EU, as these individuals have the appropriate knowledge to make necessary adjustments 86 
to non-EU data to account for differences in agronomic conditions between the data donor 87 
and recipient countries.  Stakeholder consultation seemed to provide a consistent data 88 
generation process for all cases i.e. for technologies already developed and those still in the 89 
development pipeline whether for input or output traits.  The approach: 90 
 could be informed by any economic evaluation that exists; 91 
 could make adjustments to non-EU data to account for EU agronomic conditions; and 92 
 could generate new ‘notional’ data where no observational data currently existed. 93 
 94 
To maximise the quality of the data derived from the survey of stakeholders, the study 95 
employed the so-called ‘Delphi’ technique, developed at the RAND Corporation (Dalkey and 96 
Helmer, 1963). The Delphi technique takes information from a panel of well-informed 97 
individuals and builds these data into a consensus about possible future change or 98 
developments (Hsu and Sandford, 2007; Linstone and Turoff, 1975; Martino, 1993; Young 99 
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and Jamieson, 2001). The key characteristic of the Delphi process is that data gathering is an 100 
iterative process, punctuated by feedback of the group results to all contributing individuals. 101 
In light of this feedback individuals are then permitted to amend their judgements until an 102 
acceptable measure of consensus is reached. Multiple iterations are sometimes required to 103 
derive an acceptable level of consensus. Data can be collected in a group setting, or 104 
anonymously, as this is an effective way of reducing the biasing effects of dominant 105 
individuals operating in group settings such as focus groups (Dalkey, 1972; Scott, 2011).   106 
 107 
The Delphi technique has become a well-accepted means of using expert opinion to help 108 
anticipate future events in many technological, social and political fields. It has also been 109 
used to explore a diverse range of issues in the realm of food and agriculture, for example: 110 
policy forecasting (Fearne, 1986); anticipating biotechnology trends (Menrad et al, 1999); 111 
food supply chain developments (Ilbery et al, 2004); scoping the role of agriculture in flood 112 
management (Kenyon et al, 2008); analysis of the drivers of past Common Agricultural 113 
Policy (CAP) reform rounds (Cunha and Swinbank, 2009); examining sustainable upland 114 
rural estate management (Glass et al, 2013); prioritisation of management strategies to 115 
control zoonotic diseases (Stebler et al, 2015); and evaluation of vegetation management 116 
strategies under electric power lines (Dupras et al, 2016). 117 
 118 
 119 
In this paper, we report the results of a global Delphi survey consultation into the potential 120 
agronomic and economic benefits that 12 prospective GM crop-trait combinations might 121 
offer to EU farmers and/or consumers.  In addition, the paper also addresses the question of 122 
the significance of any estimated benefits identified i.e. asking the question ‘how much 123 
difference would these benefits make to the competitiveness of adopters compared to non-124 
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adopters?’  Past experience suggests that once these technologies are licensed for use in a 125 
country, if they offer any worthwhile benefit, the vast majority of farmers quickly adopt 126 
them.  This assumption is based on observation of the very rapid and near complete market 127 
penetration of Herbicide Tolerant (HT) canola in Canada (James, 2014). Some past studies 128 
modelled the likely rate of uptake of GM technologies in various countries (e.g. Dillen et al., 129 
2009) but these estimates were based on simple assumptions of the speed and nature of GM 130 
adoption patterns of similar GM technologies in non-EU countries.  As such approaches can 131 
be criticised, the simplifying assumption was made that, for each crop trait included in this 132 
evaluation, maximum penetration had been achieved. For this reason, rather than examine the 133 
potential benefits received by individual farmers of adoption of these GM technologies, it 134 
made more sense to explore the issue of the competitive advantage conferred on countries 135 
that adopt them, compared to competitors that do not. To do this, the input and output 136 
impacts of the GM traits estimated in the stakeholder consultation were applied to standard 137 
‘representative’ crop cost models for a selection of EU countries (see Method section for 138 
more detail). In this exercise it was assumed that these GM technologies are taken up in the 139 
UK and the impact of this on the competitiveness of UK production, relative to a selection of 140 
northern EU countries, is assessed. The choice of the UK as the experimental platform for 141 
this competitiveness analysis is made more pertinent by the recent Brexit vote in the UK. As 142 
a consequence of this public vote, the UK will find itself outside of the EU GM licensing 143 
framework and free to follow its own GM licensing policy. Recent UK governments, guided 144 
by scientific evidence, have been notably less sceptical of GM technologies than 145 
governments in many EU countries and the European Commission and Parliament. It is, 146 
therefore, likely that the effective moratorium on GM licensing seen in the EU will not be 147 
replicated in an independent UK. It would, therefore, be instructive to explore what impact 148 
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the adoption of GM technologies would have on the relative competitiveness of the UK 149 
agriculture sector. 150 
 151 
2. Method 152 
While there were many crop-trait combinations in the market, or under development, not all 153 
of these would be suitable for EU agronomic conditions, or offer traits that would provide 154 
benefits in the EU.  A literature review was used to select appropriate candidates from within 155 
this population of options through the identification of the need for a trait to meet a particular 156 
EU agronomic challenge or, by identifying a particular crop-trait combination already 157 
discussed in the literature which might offer benefits in the EU context, for example by 158 
helping to overcome a common EU pest problem or climatic limitation (see Ricroch & 159 
Hénard-Damave, 2016; Hefferon, 2015; De Steur et al., 2015; and the GM Foods Platform 160 
(FAO, 2015)).  Using these selection criteria, the EU FP7 AMIGA project team selected 161 
relevant crop-trait combinations from three official government databases of applications for 162 
release of GM material to the environment: the USDA APHIS database of field tests of GM 163 
crops (USDA, 2015); the EU GMO Register (JRC, 2015); and the Australian Applications 164 
and Authorisations for Dealings involving Intentional Release (DIR) database (OGTR, 2015).  165 
The subset of crop-trait combinations selected is presented in Appendix 1, which classifies 166 
crop-trait combinations into two broad types. First, those that have already secured USDA 167 
de-regulated status and therefore either have, or legally could be, commercialised, and 168 
second, those still undergoing trials and awaiting de-regulation.  169 
 170 
The traits identified in Appendix 1 are expressed as broad phenotype classes. However, 171 
within these broad classes, several specific technologies might exist. For example, the 172 
phenotype class HT captures multiple technologies providing tolerance to a number of 173 
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different herbicide compounds. Because of this, the counter-intuitive phenomenon is seen in 174 
Appendix 1 that field trials are still being undertaken in a phenotype class even though some 175 
representatives of that class have already achieved USDA deregulated status. Continuing the 176 
use of the HT class as an example, this occurs where developers are trying to produce HT 177 
crops tolerant either to different herbicides, or multiple herbicides as stacked traits. In the 178 
APHIS database, not only have some individual technologies been de-regulated, but they 179 
have also been commercialised, and so are currently available for uptake by farmers in some 180 
countries. To illustrate, 67% of the area of maize grown in the USA in 2013 was stacked 181 
herbicide tolerant/insect resistant (HT/IR) (Fernandez-Cornejo et al, 2014), while drought 182 
tolerant maize was grown on 275k ha (0.3% of the total area) in the USA in 2014 (James, 183 
2014).  184 
 185 
The shortlisted crop-trait combinations identified by means of this review process, had the 186 
following characteristics: 187 
 the technology had either achieved USDA de-regulated status, or was undergoing 188 
field trials towards that objective, either in the USA, the EU or Australia; 189 
 the technology is agronomically suitable for EU agriculture; and 190 
 examples of this technology are either already available in the global marketplace, or 191 
stand a very good chance of being so by 2025. 192 
The subset of 12 crop-trait combinations were further classified on the basis of whether their 193 
traits offer benefits on the input side to the farmer or grower, i.e. improved agronomic 194 
properties or, on the output side, that enhance, or modify the harvested product qualities, as 195 
shown in Appendix 1. 196 
 197 
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To carry out the Delphi study, a panel of stakeholders was recruited with expertise in GM 198 
issues from various professional sectors such as: crops research and development; arable 199 
farming; crop protection; and farm management.  Invitations to participate in the study were 200 
sent to 212 individuals that had either been engaged in GM research i.e. authors of GM-201 
related papers in peer-reviewed journals, or who were participants at recent GM-related 202 
conferences and technical meetings. These 212 individuals were drawn from a range of 203 
institutional backgrounds, with the largest group being university academics (43%), followed 204 
by commercial or government research scientists (20%) and government officials (20%).  In 205 
terms of geographical location, 68% of the experts were based in Europe, 24% in North 206 
America, and 8% from other parts of the world. 207 
 208 
An explanatory recruitment letter and a one-page questionnaire were e-mailed to the panel of 209 
experts in August 2015, and a reminder sent 30 days later, as a means to increase response 210 
rate. A total of 51 replies were received, 26 of which were sufficiently complete to be 211 
included in the final panel (an effective response rate of 12.3%).  Twenty five responses were 212 
unusable, for the following reasons: 10 said they had no relevant knowledge; while 15 213 
declined to participate for other assorted reasons. The response rate of experts working in 214 
commercial companies was much higher than for the other categories and so their weight in 215 
the final panel is greater than in the original sampling frame.  216 
 217 
Whilst the research team would have preferred to have had a Delphi panel of more than 26, 218 
we can say, without revealing confidential details of the panel, with a degree of certainty that 219 
they were very experienced and possessed expert knowledge of the subject matter under 220 
investigation.  As such they were both an appropriate and relevant panel for the study. 221 
 222 
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The second round consultation document was sent out to panel members 60 days after the 223 
first mailing.  In the second round, each panel member, after being reminded of their own and 224 
the panel’s average first round estimates, was invited to confirm or amend their original 225 
estimates. Of the 26 panel members, 13 replied in the second round, of whom seven made 226 
revisions to their first round estimates, while the remainder indicated that they were happy 227 
with their original estimates. For those who did not respond to the second round consultation, 228 
we could only assume that they were content to retain their original estimates. Under this 229 
assumption, the sample sizes in rounds one and two remained the same. 230 
 231 
While more than two iterative consultation rounds are permissible in the Delphi approach, a 232 
third estimation round was not considered useful in this case because, as elaborated in the 233 
results section below (see Tables 1 and 2), the standard deviation scores associated with the 234 
group mean did not change significantly between rounds one and two, suggesting that further 235 
significant reductions in the heterogeneity of the estimates would be very unlikely. The 236 
estimates that the stakeholders were asked to make related to: (i) the impacts of the GM 237 
technologies on crop yield and production costs for input-side traits; and (ii) production costs 238 
and potential market price premia for the output-side traits. These estimates were expressed 239 
in percentage terms, referenced against those for conventional crops in 2015.  Price effects 240 
can, therefore, be assumed to be expressed in constant price terms. 241 
 242 
The analysis of the impact of these GM technologies on competitiveness was undertaken 243 
through application of revised costs i.e. estimates by the consultees of GM impacts on yield, 244 
production costs and product prices, as shown in Tables 1 and 2, to models of the cost of crop 245 
production for a number of countries using a partial budgeting approach.  As data for the full 246 
costs of production were available, the impact of the uptake of GM technologies on enterprise 247 
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Net Margin was estimable.  This relatively simple approach to benefits estimation, which was 248 
chosen due to constraints on data availability, was adopted in several past studies which also 249 
had the same relatively narrow focus on the estimation of producer economic benefits e.g. 250 
Flannery et al. (2004).  Data for these representative cost models was derived from official 251 
sources i.e. EC directorates and national Departments and Ministries of Agriculture, as well 252 
as Government Agencies and commercial providers of benchmarking data.  These data 253 
represent country-wide ‘average’ costs of production for non-GM crops in the case-study 254 
countries and were derived from representative survey data.  255 
 256 
3. Results 257 
3.1 Introduction 258 
Summary results from the Delphi survey are presented in Table 1 (input-side traits) and Table 259 
2 (output-side traits). These tables present the mean estimates from the whole panel of 260 
consultees for both rounds of consultation, together with a measure of the change in the 261 
variability found in these estimates from first to second round i.e. the change in standard 262 
deviation (SD) score.  263 
 264 
When SD change scores are generally negative, this implies that the SD of the sample 265 
estimates (i.e. the extent of variation between individuals) is decreasing between rounds as 266 
the panel closes in on consensus. When the SD change estimates are also small, this suggests 267 
that there is relatively little change in the SD estimates between rounds, i.e. convergence has 268 
already largely been reached and that further iterations would only yield very small marginal 269 
reductions in variation. Statistical testing, using the Paired Comparison Students’ t test at the 270 
5% level, confirmed no significant difference (p>0.05) in the variability between the mean 271 
estimates of the two rounds, thus signalling no need for a further round of consultation. 272 
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Table 1.  Experts’ views on the likely effect of adopting various GM crops with input traits 273 
on farmers’ costs and the yields obtained. 274 
 Mean farmers’ cost change (%)   Mean farmers’ yield change (%) 
 1st 
round 
 
SD 
2nd 
round2 
 
SD 
SD 
change1 
 1st 
round 
 
SD 
2nd 
round2 
 
SD 
SD 
change1 
Potato - insect 
resistant 
-4.55 10.23 -4.47 6.49 -3.74  3.85 7.23 3.75 5.89 -1.34 
Potato - 
pathogen 
tolerant 
-6.38 15.58 -5.89 12.63 -2.95  9.26 8.56 9.14 7.58 -0.98 
Wheat - 
drought tolerant 
2.55 7.81 2.38 7.33 -0.48  6.85 9.40 8.00 8.32 -1.08 
Soybean - 
herbicide 
tolerant 
-5.75 12.85 -4.93 10.52 -2.33  4.28 6.34 4.07 5.04 -1.30 
Sugarbeet - 
herbicide 
tolerant 
-5.66 15.70 -4.70 13.18 -2.52  4.45 7.04 4.19 5.89 -1.15 
Maize - drought  
tolerant 
0.68 8.49 0.80 7.16 -1.33  6.08 8.32 6.73 7.15 -1.17 
Maize -  
herbicide 
tolerant and 
insect resistant 
-5.25 13.79 -4.90 12.41 -1.38  6.81 9.99 6.45 8.69 -1.30 
Notes: 275 
1 SD change is the SD value in the second round minus the value in the first round. 276 
2 Differences in first and second round mean cost and yield changes were tested for statistical significance using 277 
the Students’ t test at the 5% level, and no significant differences were found. 278 
 279 
Table 2.  Experts’ views on the likely effect of adopting various GM crops with output traits 280 
on farmers’ costs and prices for the crops received. 281 
 Mean farmers’ cost change (%)  Mean farmers’ price change (%) 
 1st 
round 
 
SD 
2nd 
round2 
 
SD 
SD 
change1 
 1st 
round 
 
SD 
2nd 
round2 
 
SD 
SD 
change1 
Wheat - with 
improved 
bread-making 
properties 
5.29 5.42 5.47 5.22 -0.20  6.26 4.38 6.33 4.35 -0.03 
Wheat - with 
reduced levels 
of protein 
linked to 
celiac disease 
5.29 5.91 5.47 5.73 -0.18  9.06 7.48 9.50 7.38 -0.10 
Soybean - 
with 
improved 
nutritional 
5.13 4.99 5.26 4.81 -0.18  7.47 6.34 8.03 6.41 0.07 
13 
 
profile 
Oilseed rape - 
producing 
Omega 3 oils 
as a dietary 
supplement 
5.39 5.83 5.23 5.67 -0.16  9.21 6.07 8.93 5.32 -0.75 
Oilseed rape - 
with a lower 
lower 
saturated fat 
content 
4.87 4.81 5.00 4.62 -0.19  6.63 5.25 6.68 5.18 -0.07 
Notes: 282 
1 SD change is the SD value in the second round minus the value in the first round. 283 
2 Differences in first and second round mean cost and price changes were tested for statistical significance using 284 
the Students’ t test at the 5% level, and no significant differences were found. 285 
 286 
3.2 GM crops with input traits 287 
Input-side traits offer the prospect of financial benefits to farmers from reduced input costs, 288 
especially crop protection costs (such as less expenditure on herbicides and pesticides), and 289 
increased revenue through improved (or protected) yields. Table 1 shows that the panel 290 
anticipated cost savings from five out of seven input-side traits, but increases in production 291 
costs in the remainder. Costs savings ranged from 4.47% to 5.89%, a relatively narrow range, 292 
with these being somewhat larger in magnitude than the range of expected cost increases i.e. 293 
0.80% to 2.38%.  294 
 295 
The crop-trait combinations offering the largest savings in input costs are pathogen tolerant 296 
(PT) potato (5.89%) and HT soybean (4.93%).  At the other end of the spectrum, the panel 297 
thought that drought tolerant wheat would raise farmers’ costs by 2.38% due to the fact that 298 
there would be no crop protection cost savings to compensate for higher seed costs. The 299 
notion of increased production costs for drought tolerance makes perfect sense because, with 300 
the possible exception of reducing the need for irrigation, these traits do not replace any 301 
inputs, such as sprays, but they may incur higher seed costs. However, these traits may still 302 
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prove financially advantageous if their yield protection benefits, in years of drought, offset 303 
the higher seed costs when averaged over the longer term.   304 
 305 
The highest and lowest anticipated yield improvements (Table 1) are both recorded for 306 
potatoes, with IR potato estimated to lift yield by 3.75%, and PT potato by 9.14%. This 307 
suggests a panel consensus that current yield losses from insect pests, e.g. Colorado and Flea 308 
Beetles, are considerably lower than yield losses from diseases, such as Brown Rot and Late 309 
Blight. It is informative to note that most of the recent GM potato trials globally have been 310 
for late blight resistance. Drought tolerance is estimated to offer greater potential yield 311 
benefits than the average, at 8% for wheat and 6.73% for maize. These estimates are high 312 
considering that they represent yield protection averaged over a number of years. This 313 
strongly suggests the stakeholder view that yield losses in drought years might be 314 
catastrophic. Herbicide resistance traits are estimated to offer slightly below average yield 315 
improvements for both sugar beet (4.19%) and soya bean (4.07%).   316 
 317 
 3.3 GM crops with output traits 318 
The panel anticipated that all of the crops with output-side traits would incur increased 319 
production costs compared to the conventional equivalent (see Table 2). These cost increases 320 
would be due, almost in their entirety, to higher seed costs, as biotech companies attempt to 321 
recoup their investment in product development. The stakeholder panel provided a pretty 322 
narrow range of production cost increases across crop-trait combinations, with a range of just 323 
0.47%. Interestingly, the crop expected to incur the largest increases in production (seed) 324 
costs, is wheat, i.e. 5.47% for both output traits. Here, stakeholders may be factoring in the 325 
fact that wheat is a relatively high value crop (per hectare), and so can better support higher 326 
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seed prices than some other crops. At the other end of the scale, the output trait with the 327 
smallest increase in production costs was OSR with lower saturated fat content (5.0%). 328 
 329 
All of the nutritional profile changes identified for GM crops were viewed as being desirable 330 
to consumers and, so, all were expected to offer a price premium to the farmer. However, 331 
they all represent niche markets so only a fairly small sub-set of farms would be able to grow 332 
them. The highest price premium was anticipated for wheat with reduced levels of protein 333 
linked to celiac disease (9.5%), although this would only be a niche market product.  Oilseed 334 
rape producing Omega 3 oils as a dietary supplement was also expected to offer a substantial 335 
premium (8.93%). The crop with the lowest estimated premium, by comparison, was wheat 336 
with improved bread making properties (6.33%). This slightly lower premium, in 337 
comparison, may be due to the fact that the gains to bread and biscuit makers from the new 338 
properties would be only marginal, as this trait would not allow for any new differentiation in 339 
the market and so a higher retail price would not be obtainable.  However, the panel did not 340 
give any ‘hard’ evidence in this respect. 341 
 342 
3.4 Impact of the ‘new’ crops on competitiveness 343 
The significance of these GM technologies i.e. their impact on competitiveness, was explored 344 
by comparing GB enterprise production costs and market returns (i.e. sales value without 345 
subsidy), both with and without GM, to equivalent non-GM production in selected EU 346 
countries.  Figure 1 shows the impact of GM adoption on competitiveness, as expressed by 347 
market returns and net margin for output-side traits, and operating costs and net margin for 348 
input-side traits. The adopter country (i.e. where GM technologies have been applied) is GB 349 
agriculture for six out of eight crop-trait combinations, but France had to be used in the two 350 
grain maize cases, as grain maize production does not occur in GB.  351 
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 352 
Figure 1 suggests that, assuming widespread adoption, the selected GM traits could improve 353 
the competitive position of GB agriculture compared to non-adopting EU counterparts. The 354 
way in which this improvement in competitiveness is achieved varies according to trait. For 355 
input-side traits, competitiveness is improved by reducing production costs. For example, in 356 
the case of potatoes, current GB production costs are roughly equivalent to those in the 357 
Netherlands. However, the adoption of GM pest control technologies for this crop i.e. HT and 358 
pathogen tolerance (PT) would reduce average GB production costs by 4.5% and 5.9% 359 
respectively (see Table 1) to a level significantly below that in the Netherlands.  If these cost 360 
savings could be passed on to consumers in the form of lower prices, GB potatoes could, 361 
perhaps, compete for market share in the Netherlands, despite the additional transport costs.  362 
 363 
In the case of output traits, the panel thought that costs of production are, more often than not, 364 
expected to increase, as in the case of OSR with enhanced Omega 3 content, where 365 
production costs were projected to rise by 5.2% (see Table 2).  Whilst this would lead to 366 
higher consumer prices if consumers placed a higher value on this ‘enhanced’ product, they 367 
would be willing to pay these higher prices. If the monetised value that consumers placed on 368 
the enhanced product was greater than the production cost increases, then a producer (price) 369 
surplus would be available, as indeed is projected in this case, with an expected rise in 370 
producer price of 8.9% (see Table 2). Competitive advantage would also be improved 371 
through gaining access to a niche market that non-adopters could not exploit. 372 
 373 
Figure 1. Impact of the uptake of selected GM technologies on the competitiveness of crop 374 
production in Great Britain and various EU countries. 375 
 376 
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 377 
 378 
Sources: EC (2016b); AHDB (2015); Defra (2013); Rezbova et al. (2013); USDA (2012); AgriBenchmark 379 
(2016); and EC (2012). 380 
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Note: Wheat and grain maize enterprise data are based on FADN whole-farm data for farms specialising in 381 
those crops. 382 
Note: Potato prices are based on a 3-year average centred on 2012 to smooth out extreme annual variation. 383 
Note: Data originally denominated in £ Sterling have been converted to Euros, assuming an exchange rate of 384 
£1=€1.2. 385 
Note: NL sugar beet production costs (2012) are assumed to be the same as in DE. 386 
Note: The average EU rapeseed price (2012) has been used for DE and FR. 387 
 388 
Competitiveness is also indirectly improved, for all traits considered here, through increased 389 
profit (i.e. Net Margin). More profit means more capital is available for investment in: 390 
technological innovation through new machinery purchases; land purchases to spread fixed 391 
costs; or through enhanced training and advisory services. These investments drive increases 392 
in technical and managerial efficiency, thereby securing further improvements in 393 
competitiveness. Improvement in competitiveness of this kind is best exemplified by wheat 394 
with improved bread-making properties (see Figure 1). GB adoption of this GM technology 395 
would increase wheat production costs by 5.5% i.e. rising above average costs in Germany, 396 
but would elevate profits by 8.1% through an increased price premium (of 6.3%), thereby 397 
enhancing the prospect of additional future UK investments leading to improvements in 398 
efficiency. 399 
 400 
3.5 Identification of other crop-trait GM combinations that might become available 401 
The selection of crop-trait combinations used in the study reported here was made on the 402 
basis that the technologies were either already in the market, or well along the development 403 
pipeline and would also offer potentially significant benefits to EU farmers or consumers. 404 
These particular crop-trait combinations were chosen because they captured the most 405 
important trait types, across a range of major crops. To guard against the possibility that 406 
important crop-trait combinations had been omitted from the Delphi consultation, panel 407 
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members were asked to suggest any such alternatives that also met the selection criteria.  408 
Only a small number of GM crop-trait combinations were suggested by the panel, these being 409 
dominated by output-side traits i.e. various types of biofortification. Most of these output-side 410 
traits would supply niche markets, which are by nature, small. Therefore, there would only be 411 
very limited opportunities to tap into these markets to secure a price premia. Such traits, 412 
therefore, offer only modest benefits for the broader farming sector and wider society. In light 413 
of this it is, perhaps, not damaging to the analysis presented here that some GM traits of this 414 
type have been omitted. Of course, some output-side traits, for example vitamin fortification, 415 
might not be confined to niche markets but could, in theory, displace all conventional 416 
production. However, while the potential market for such traits is, in theory, very large, the 417 
scale of the benefits to both farmers and wider society within the EU are likely to be small. 418 
There are two reasons for this. First, when a GM crop displaces its conventional equivalent, 419 
even if some additional societal benefit is being supplied, market prices tend to drop to the 420 
same floor as in the former conventional market. Second, in any developed country where 421 
diets are already nutritious and where many fortified processed products already exist, the 422 
price premium for a biofortified commodity would be small, reflecting the small marginal 423 
societal gain. 424 
 425 
A minority of the panel of stakeholders, when asked to identify prospective GM technologies 426 
that were not included by our review, pointed away from traditional GM technologies instead 427 
to the products of new plant breeding techniques (NPBTs), such as CRISPR, which do not 428 
use transgenesis.  Although relatively new, techniques such as CRISPR are already being 429 
hailed (for example, see Belhaj et al, 2013; and Ledford, 2015) as the future industry standard 430 
tool for biotechnology, thereby likely to supplant GM in plant breeding. While the status of 431 
these NPBTs are currently still being debated by advisory bodies and regulatory authorities in 432 
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the EU (Tagliabue, 2016), the hope is that because they produce plant gene modifications that 433 
are indistinguishable from both conventional breeding and chemical and physical 434 
mutagenesis, they will be excluded from the scope of GM legislation such as Directive 435 
2001/18/EU on Deliberate Release of Genetically Modified Organisms. This would make 436 
releases of such crops to the EU market much more routine. 437 
 438 
4. Discussion and conclusions 439 
Our choice of a stakeholder consultation approach for generating estimates of likely yield, 440 
cost and revenue changes resulting from future EU (or UK) adoption of GM crops allowed a 441 
nuanced transfer of data from non-EU settings into the EU context where crop-trait 442 
combinations have already been developed and has also allowed for the generation of ‘novel’ 443 
data where crop-trait combinations are still in development. The extent of the challenge 444 
facing the consultees in transferring data from non-EU settings depended on several factors, 445 
including perceptions of whether there are likely to be differences in seed costs, or agronomic 446 
differences between the EU and non-EU settings that had to be accounted for, plus 447 
differences in disease pressure and pest management practice.  448 
 449 
Another important consideration that consultees had to account for was the likely costs 450 
associated with required co-existence measures in adopter countries, as these could impact 451 
considerably on production costs. The specific measures that might be put in place in the 452 
adopter countries for individual crops could not, perhaps, be easily anticipated, so it is not 453 
exactly clear how consultees handled this issue. However, it is likely that reference would 454 
have been made to the impact of co-existence measures on production costs in countries that 455 
had already adopted similar GM technologies. It is also worth pointing out that the existence 456 
of co-existence measures in these non-EU countries has not acted either as a barrier to rapid 457 
21 
 
uptake, nor significantly eroded the financial benefits that the technology confers (see, for 458 
example, Furtan et al, 2007), including the case of GM maize in Spain and Portugal.  459 
 460 
The cross-country analysis reported here provides a useful indicator of the impacts that GM 461 
crop adoption would have on national competitiveness. However, it should be recognised that 462 
this analysis presents a somewhat simplified picture of possible future adoption decisions. 463 
First, the analysis assumes near complete uptake of these GM technologies in the adopter 464 
country. While this must be a reasonable assumption for some of these GM technologies 465 
based on historic observation, for example PT potatoes would likely be widely adopted as all 466 
growers could benefit.  However, this might not be the reality for some crop-trait 467 
combinations, for example where the GM technology targets a particular pest problem that is 468 
not present in all regions within a country. A historical example of this would be the adoption 469 
of IR maize in Portugal, where uptake has been confined to regions where 470 
European/Mediterranean Corn Borer presents a significant commercial risk (Jones et al, 471 
2017). For crops with limited potential for market penetration, for example DT maize, the 472 
results of the competitiveness analysis should not be interpreted as indicating the impacts for 473 
the competitiveness of the countries as a whole.  474 
 475 
Second, the data used in the representative cost models are reflective of the central tendency 476 
in each case-study country. In reality, a wide distribution of production costs exists in each 477 
country, due to diversity in farmers’ management ability, agronomic factors and geographic 478 
location. This means that changes to the competitive advantage resulting from GM adoption 479 
would not be uniformly experienced amongst producers in any country.  480 
 481 
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Third, the consultees’ estimates of GM impacts in costs and yields are themselves also 482 
measures of central tendency, obscuring a likely broad range of impacts experienced by 483 
individuals, where some, due to their particular circumstances, may not receive significant 484 
benefits from the technology. Finally, the possibility must be considered that the consultees, 485 
in considering the impacts of the GM technologies on production costs, did not properly 486 
factor in possible increases in costs associated with some potential negative externalities of 487 
adoption of GM technologies, such as increase in pest resistance through the use of HT or IR 488 
events (Green & Owen, 2011; Brookes, 2014). In such circumstances, additional 489 
management actions are required to control the problem, perhaps involving applications of 490 
alternative pesticides requiring more sprayer passes, or other approaches to pest control, such 491 
as changed rotations, or use of deep mechanical tillage.  492 
 493 
Whilst resistance problems can be controlled by careful use of conventional management 494 
techniques, the need to undertake them can remove some, or all, of the cost saving benefits 495 
from the use of the technology (Green & Owen, 2011). Numerous other studies have claimed 496 
a range of environmental and social dis-benefits arising from the widespread adoption of GM 497 
technologies, such as gene-flow to non-GM crops (Mallory-Smith & Zapiola, 2008) and wild 498 
relatives (Warwick, et al., 2008; Reichman, et al., 2006), damage to wildlife (Garcia & 499 
Altieri, 2005) and even economic risks to non-GM producers through adventitious 500 
contamination (Blakeney, 2016). There is insufficient space to critique these studies and 501 
claims here, although it is worth noting that several authors have cogently argued that the 502 
environmental and socio-economic benefits of GM crops far outweigh any negative 503 
externalities (Brookes & Barfoot, 2016).  Whilst this lack of detailed critique may seem 504 
unsatisfying to some, it should be pointed out that for the analysis here there is the 505 
requirement to do so, as the focus of the study reported here is on the impacts of adoption of 506 
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GM technologies in the EU on potential producer surplus, rather than consumer, or wider 507 
societal surplus. 508 
 509 
The historic policy environment in the EU has resulted in an effective moratorium on GM 510 
releases to the environment. With most consumers, campaigning groups and politicians 511 
across the EU remaining largely hostile to the production of GM crops and the consumption 512 
of their products, it is understandable that many of the stakeholders consulted were of the 513 
view that the current informal moratorium on GM authorisations would remain in place for 514 
the foreseeable future. While the GM policy environment has changed in the last few years, 515 
there is still great uncertainty over whether this will make GM authorisations more likely, as 516 
many states are likely to execute the opt-outs permissible under the new legislation.  For 517 
example, it is already known that 19 Member States had applied for the opt-out prior to the 518 
3 October 2015 deadline for applications to the Commission, including: Germany, France, 519 
Italy, Austria, Greece, Hungary, Latvia, Lithuania and Poland (New Scientist, 2015).  520 
Additionally, even if authorisations begin to flow, it is not known whether GM crops would 521 
actually be accepted into these national markets by retailers and consumers.  522 
 523 
The uncertainty revealed here by our consultation over the future market and policy 524 
environment will, of course, do little to change the attitudes of biotech companies towards 525 
investment in biotechnologies targeted at EU agronomic conditions or, indeed, those seeking 526 
authorisations for GM crops to be grown in the EU. If this generally pessimistic stakeholder 527 
outlook is a harbinger of restrictive future EU policies, and is a disincentive to biotech 528 
companies to invest in GM crops targeted at EU agriculture, then the benefits associated with 529 
GM crops identified here must be viewed, in essence, as benefits that will be foregone by the 530 
great majority of EU farmers.   531 
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 532 
In terms of the scale of these benefits foregone, the study reported here has shown that the 533 
competitiveness of the agricultural sector in EU Member States could very well be improved 534 
by adoption of GM crops.  However, these improvements, when averaged over all farmers in 535 
a country, would still be relatively small-scale, to the extent that existing large-scale natural 536 
advantage, resulting from relatively durable macro-economic or environmental conditions, is 537 
very unlikely to be overturned. For example, the adoption of HT/IR grain maize in France 538 
would, in terms of country-wide averages, overturn the current small competitive advantage 539 
that Italy holds, but would do little to eliminate the much more significant competitive 540 
advantage (resulting from lower costs of production) held by Germany. Adoption of GM 541 
crops would, therefore, not be a game changer for countries with high production costs, 542 
although they would, based on the evidence generated in the study reported here, make a 543 
positive contribution with respect to competitiveness in any country that adopts them. 544 
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Appendix 1.  The various GM crops, and their traits, shortlisted for the Delphi survey.  
Crop Phenotype class Year of first field 
test notification 
(APHIS) 
IP owners (trials in last 5 years) No. of 
trials in 
last 5 
years 
USDA unregulated 
status granted (and 
IP owners)? 
Sources used to 
identify suitability 
for EU agriculture 
Maize Drought tolerance Unknown Pioneer Hi-Bred International Inc;  
Monsanto. 
>15 Yes 
 
Pioneer Hi-Bred 
International Inc.; 
Monsanto; 
BASF; 
Syngenta. 
Ferrero et al (2014) 
Tolk et al (2016) 
Maize HT-IR stacked 1992 
Pioneer Hi-Bred 
International Inc 
Monsanto & Monsanto Europe, S.A.; 
Syngenta Crop Protection LLC; 
Pioneer H-Bred International Inc; 
Dow AgroSciences LLC; 
Genective SA; 
Bayer CropScience; 
Genective SA; 
Instituto Nacional de Investigación y 
Tecnología Agraria y Alimentaria 
(INIA). 
>15 Yes 
 
Monsanto; 
Pioneer Hi-Bred 
International Inc.; 
Syngenta; 
Aventis; 
Novartis Seeds. 
 
Baktavachalam et al 
(2015) 
Ruffo et al (2015) 
Potato IR 1990 
Monsanto 
Michigan State University. >15 Yes  
 
Monsanto; 
Frito Lay; 
USDA; 
Calgene. 
Haeseart et al (2015)  
Jo et al (2014) 
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Crop Phenotype class Year of first field 
test notification 
(APHIS) 
IP owners (trials in last 5 years) No. of 
trials in 
last 5 
years 
USDA unregulated 
status granted (and 
IP owners)? 
Sources used to 
identify suitability 
for EU agriculture 
Potato Fungal resistance 
(FR) 
1990 
Washington State 
University 
J.R. Simplot Company; 
Michigan State University; 
Betaseed inc.; 
John Innes Centre, UK; 
Swedish University of Agricultural 
Sciences SLU; 
Wageningen University; 
Teagasc; 
BASF Plant Science GmbH; 
Queensland University of  
Technology. 
>15 Yes 
 
USDA; 
Monsanto; 
Washington State; 
Frito Lay. 
Haeseart et al (2015)  
Jo et al (2014) 
Sugar 
beet 
HT 2004 
Syngenta 
Betaseed inc; 
Ses Vanderhave NV; 
Syngenta Crop Protection AG; 
Plant Production Research Center 
Piestany, Bratislavska cesta; 
KWS SAAT AG; 
SESVANDERHAVE N.V.; 
Monsanto Europe SA. 
5-10 Yes 
 
American Crystal 
Sugar Company; 
Syngenta; 
Betaseed; 
Ses Vanderhave NV. 
Dillen et al (2013) 
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Crop Phenotype class Year of first field 
test notification 
(APHIS) 
IP owners (trials in last 5 years) No. of 
trials in 
last 5 
years 
USDA unregulated 
status granted (and 
IP owners)? 
Sources used to 
identify suitability 
for EU agriculture 
Soyabean HT 1989 
Monsanto 
Pioneer H-Bred International Inc; 
M.S. Technologies LLC; 
Monsanto; 
Bayer CropScience; 
University of Georgia; 
USDA; 
Iowa State University; 
University of South Carolina Aiken; 
BASF Plant Sciences LLC; 
DAS LLC; 
Syngenta; 
Montana State University; 
OSU-OARDC. 
>15 Yes 
 
University of Georgia; 
Upjohn; 
Northrup King; 
Pioneer Hi-Bred 
International Inc; 
M.S.Technology LLC; 
Monsanto. 
Brookes (2003) 
Soya 
bean 
PQ (improved 
nutritional profile) 
1993 
Du Pont 
Pioneer H-Bred International Inc.; 
University of Kentucky; 
USDA; 
University of Minnesota; 
Monsanto; 
University of Missouri; 
University of Nebraska/Lincoln; 
University of Kentucky; 
Montana State University. 
>15 Yes 
 
Du Pont; 
Monsanto; 
Pioneer H-Bred 
International Inc. 
Sowa et al (2014) 
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Crop Phenotype class Year of first field 
test notification 
(APHIS) 
IP owners (trials in last 5 years) No. of 
trials in 
last 5 
years 
USDA unregulated 
status granted (and 
IP owners)? 
Sources used to 
identify suitability 
for EU agriculture 
OSR 
/canola 
PQ (Lower 
saturated fat 
content) 
1991 
Calgene 
None None Yes 
 
Calgene; 
Cargyll; 
InterMountain Canola; 
Du Pont. 
Batista et al (2011) 
Wheat Heat/drought 
tolerance 
1998 (Montana 
State University) 
Syntech Research; 
Arcadia Biosciences; 
University of Nebraska; 
Southern Illinois University; 
Monsanto; 
Biogemma USA. 
>15 No Farooq et al (2014) 
Aschonitis et al (2013)  
Yadav et al (2015) 
OSR 
/canola 
PQ (higher Omega 
3 oils) 
2014 
Nuseed Americas 
Nuseed Americas. 1-4 No Batista et al (2011) 
Wheat PQ (Biologically 
safe, e.g. for 
coeliacs) 
2011 
Washington State 
University 
Washington State University. 1-4 No Gil-Humanes et al 
(2010) 
Wheat PQ (improved 
bread-making 
quality) 
2003 
Montana State 
University 
USDA; 
Murdoch University, Australia. 
5-10 No Graybosch et al (2013) 
 
